SpringWorks (SWTX) | Financial Analysis & Statements
SpringWorks Therapeutics, Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
49.1M
Gross Profit
45.6M
92.81%
Operating Income
-80.5M
-164.07%
Net Income
-83.2M
-169.47%
EPS (Diluted)
$-1.11
Balance Sheet Metrics
Total Assets
505.4M
Total Liabilities
88.0M
Shareholders Equity
417.4M
Debt to Equity
0.21
Cash Flow Metrics
Operating Cash Flow
-46.4M
Free Cash Flow
-68.8M
Revenue & Profitability Trend
Quarter Income Flow
Mar 31, 2025
Annual Income Flow
2024
SpringWorks Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 191.6M | 5.4M | 0 | 0 | 35.0M |
| Cost of Goods Sold | 12.6M | 422.0K | 0 | 0 | - |
| Gross Profit | 179.0M | 5.0M | 0 | 0 | - |
| Gross Margin % | 93.4% | 92.3% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 200.5M | 150.5M | 146.1M | 101.7M | 51.9M |
| Selling, General & Administrative | 256.7M | 197.6M | 134.6M | 71.8M | 29.5M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 457.2M | 348.0M | 280.7M | 173.5M | 81.3M |
| Operating Income | -278.1M | -343.0M | -280.7M | -173.5M | -46.3M |
| Operating Margin % | -145.2% | -6,297.3% | 0.0% | 0.0% | -132.4% |
| Non-Operating Items | |||||
| Interest Income | 26.0M | 22.9M | 6.1M | 546.0K | 1.3M |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -6.0M | -5.0M | -2.9M | -988.0K | -580.0K |
| Pre-tax Income | -258.1M | -325.1M | -277.4M | -173.9M | -45.6M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -258.1M | -325.1M | -277.4M | -173.9M | -45.6M |
| Net Margin % | -134.7% | -5,968.5% | 0.0% | 0.0% | -130.2% |
| Key Metrics | |||||
| EBITDA | -274.7M | -341.3M | -279.9M | -173.0M | -46.0M |
| EPS (Basic) | - | $-5.15 | $-5.21 | $-3.59 | $-1.05 |
| EPS (Diluted) | - | $-5.15 | $-5.21 | $-3.59 | $-1.05 |
| Basic Shares Outstanding | - | 63123936 | 53290528 | 48497790 | 43300063 |
| Diluted Shares Outstanding | - | 63123936 | 53290528 | 48497790 | 43300063 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
SpringWorks Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 69.8M | 176.1M | 67.5M | 104.0M | 147.1M |
| Short-term Investments | 238.2M | 303.1M | 524.7M | 269.5M | 361.4M |
| Accounts Receivable | 46.2M | 5.9M | 0 | - | - |
| Inventory | 10.2M | 3.1M | 0 | - | - |
| Other Current Assets | 16.0M | 12.7M | 7.5M | 9.4M | 4.9M |
| Total Current Assets | 380.5M | 500.9M | 599.8M | 382.9M | 513.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 11.3M | 8.6M | 4.7M | 1.0M | 1.9M |
| Goodwill | 15.6M | 11.2M | 0 | - | - |
| Intangible Assets | 15.6M | 11.2M | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 6.5M | 4.2M | 3.2M | 3.3M | 2.6M |
| Total Non-Current Assets | 206.8M | 224.9M | 30.5M | 69.6M | 62.8M |
| Total Assets | 587.3M | 725.8M | 630.2M | 452.5M | 576.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 12.2M | 7.4M | 8.0M | 3.4M | 1.4M |
| Short-term Debt | 1.7M | 1.1M | 483.0K | 1.2M | 1.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 100.0M | 78.2M | 51.0M | 30.0M | 17.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 6.2M | 6.0M | 4.8M | 129.0K | 1.4M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | 164.0K |
| Total Non-Current Liabilities | 6.2M | 21.4M | 21.0M | 129.0K | 1.5M |
| Total Liabilities | 106.2M | 99.6M | 72.0M | 30.1M | 19.1M |
| Equity | |||||
| Common Stock | 7.0K | 7.0K | 6.0K | 5.0K | 5.0K |
| Retained Earnings | -1.2B | -895.0M | -569.9M | -292.5M | -118.6M |
| Treasury Stock | 12.6M | 4.1M | 1.3M | 0 | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 481.1M | 626.2M | 558.2M | 422.4M | 557.1M |
| Key Metrics | |||||
| Total Debt | 7.9M | 7.1M | 5.3M | 1.3M | 2.7M |
| Working Capital | 280.5M | 422.7M | 548.7M | 352.9M | 495.8M |
Balance Sheet Composition
SpringWorks Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -258.1M | -325.1M | -277.4M | -173.9M | -45.6M |
| Depreciation & Amortization | 3.5M | 1.7M | 765.0K | 490.0K | 349.0K |
| Stock-Based Compensation | 109.1M | 94.5M | 73.0M | 38.4M | 10.0M |
| Working Capital Changes | -71.3M | -11.4M | 22.9M | -185.0K | -3.2M |
| Operating Cash Flow | -215.1M | -238.6M | -179.6M | -134.2M | -37.4M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | -8.2M | -2.8M | -4.2M | 0 | -3.5M |
| Investment Purchases | -285.1M | -575.7M | -481.0M | -305.4M | -442.7M |
| Investment Sales | 378.6M | 620.7M | 279.8M | 391.0M | 28.0M |
| Investing Cash Flow | 85.2M | 42.1M | -205.4M | 85.6M | -418.2M |
| Financing Activities | |||||
| Share Repurchases | -8.4M | -2.8M | -1.3M | 0 | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -8.4M | 296.5M | 338.7M | 0 | 269.6M |
| Free Cash Flow | -196.3M | -230.2M | -171.8M | -129.9M | -32.8M |
| Net Change in Cash | -138.3M | 100.0M | -46.3M | -48.6M | -186.0M |
Cash Flow Trend
SpringWorks Key Financial Ratios
Valuation Ratios
Forward P/E
-21.96
Price to Book
8.44
Price to Sales
16.12
PEG Ratio
-21.96
Profitability Ratios
Profit Margin
-115.60%
Operating Margin
-164.07%
Return on Equity
-51.57%
Return on Assets
-28.47%
Financial Health
Current Ratio
4.33
Debt to Equity
1.77
Beta
0.70
Per Share Data
EPS (TTM)
$-3.41
Book Value per Share
$5.57
Revenue per Share
$2.95
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SWTX | 3.5B | - | 8.44 | -51.57% | -115.60% | 1.77 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| BridgeBio Pharma | 14.2B | -19.38 | -6.83 | 34.91% | -144.39% | -0.90 |
| Blueprint Medicines | 8.4B | -120.99 | 24.43 | -47.71% | -27.70% | 208.50 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.
